12:00 AM
 | 
Jul 24, 2006
 |  BioCentury  |  Strategy

Endocrine boosting

Ipsen Group says its deal with Tercica Inc. is a step towards achieving its stated goals of acquiring more products and growing its U.S. presence. And although Ipsen may end up owning up to 40% of Tercica, the latter says the deal offers it the chance to shake off its image as a one-product company while giving it financial independence through to profitability in 2010.

The deal involves the exchange of rights for two complimentary endocrine products that can be marketed by each company's existing sales force for the other product. TRCA (Brisbane, Calif.) received exclusive rights to Somatuline Autogel in the U.S. and Canada, while Ipsen (Euronext:IPN, Paris, France) received exclusive rights to TRCA's Increlex mecasermin in all territories excluding the U.S., Japan, Canada, the Middle East and Taiwan.

Canada approved Somatuline to treat acromegaly last week. IPN plans to re-file an NDA for the product, which received an FDA approvable letter in 2003 asking for more carcinogenicity and cardiac safety data. The somatostatin analog is marketed in Europe to treat acromegaly and neuroendocrine tumors.

Since its launch in Europe in 2002, Somatuline has been eating into sales of the leading somatostatin analog, Sandostatin LAR from

Read the full 992 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >